On November 28, 2023, Guangshengtang (300436.SZ) announced that on November 28, 2024, the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Catalogue (2024)" will be released, to be implemented starting January 1, 2025. The oral small molecule 3CL protease inhibitor anti-COVID-19 innovative drug Atazavir tablets (project code: GST-HG171) combined with Ritonavir tablets (trademark: Taizhongding) from Fujian Guangshengtang Pharmaceutical Co., Ltd.'s innovative drugs holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. has successfully been included in the official "National Medical Insurance Catalogue" through national medical insurance negotiations for the first time.
广生堂(300436.SZ)：子公司抗新冠病毒一类创新药泰中定成功纳入国家医保目录
Fujian Cosunter Pharmaceutical (300436.SZ): The subsidiary's innovative drug Taizhongding for combating the COVID-19 virus has successfully been included in the national health insurance catalog.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated